• Login
    View Item 
    •   UMB Digital Archive
    • UMB Open Access Articles
    • UMB Open Access Articles
    • View Item
    •   UMB Digital Archive
    • UMB Open Access Articles
    • UMB Open Access Articles
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of UMB Digital ArchiveCommunitiesPublication DateAuthorsTitlesSubjectsThis CollectionPublication DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Statistics

    Display statistics

    Factors Related to Small- and Mid-Capitalization Pharmaceutical Company Success Using Stock Performance as a Surrogate

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Author
    Ferris, Matthew J
    Sun, Kai
    Savard, Corey
    Suresh, Tejas
    Mishra, Mark V
    Date
    2021-09-23
    Journal
    Cureus
    Publisher
    Cureus, Inc.
    Type
    Article
    
    Metadata
    Show full item record
    See at
    https://doi.org/10.7759/cureus.18210
    Abstract
    Background: Developing novel pharmaceuticals demands substantial investment despite high uncertainty of success and ultimate market value. While many established drug companies are highly profitable and have large portfolios of diversified assets, much of new drug innovation, a very high-risk, high-reward gambit, stems from smaller companies striving to bring their first products to market. While drug costs, and thus pharmaceutical company profits, can be controversial, it is unquestionable that the products from these companies provide great benefit to humanity. Hence, the ongoing success of the industry as a whole is quite relevant from a public health perspective. Methodology: We sought to investigate factors influencing pharmaceutical company success using company stock performance on major US indices as a surrogate. As the profitability of large-capitalization (cap) pharmaceutical companies is well established, we focused on small- and mid-cap companies in this analysis. Small- and mid-cap pharmaceutical companies (both currently active and now defunct) and historical share prices were captured, including company details and the nature of drug pipelines. Funding by US academia was acquired via CMS.gov Open Payments and categorized into contributions < or ≥$100,000. Stock performance was considered good (+ ≥25%), mediocre (±25%), or poor (- ≥25%). Univariate and multivariate associations were assessed. Results: Of the 420 companies included in the analysis, 101 (24%) had good, 76 (18%) mediocre, and 243 (58%) poor performance. The following were associated with performance in univariate analysis: initial public offering (IPO) price (P < 0.001), time from IPO (P < 0.001), number of drug programs (P = 0.019), and academic funding (P = 0.00013), with trend for diverse pipelines (both oncology and nononcology programs under development) (P = 0.069). On multivariate analysis, IPO price was inversely associated (P < 0.0001), while academic funding (P < 0.0001) and more drug programs (P = 0.0025) were positively associated with performance. Analysis of pharmaceutical IPOs since 2000 suggests a 20% rate of outright company failure. Conclusions: The majority of included companies had lackluster stock performance, suggestive of low potential for drug development success and high probability of financial disaster. Robust drug pipelines and academic collaboration seem to be strongly related to company success.
    Rights/Terms
    Copyright © 2021, Ferris et al.
    Keyword
    biotech
    drug development
    drug pricing
    drugs
    pharmaceuticals
    stocks
    therapeutics
    Identifier to cite or link to this item
    http://hdl.handle.net/10713/16966
    ae974a485f413a2113503eed53cd6c53
    10.7759/cureus.18210
    Scopus Count
    Collections
    UMB Open Access Articles

    entitlement

    Related articles

    • Guidelines, editors, pharma and the biological paradigm shift.
    • Authors: Singh AR, Singh SA
    • Issue date: 2007 Jan
    • Late-stage Product Development and Approvals by Biotechnology Companies After Initial Public Offering, 1997-2016.
    • Authors: McNamee LM, Cleary EG, Zhang S, Salim U, Ledley FD
    • Issue date: 2021 Jan
    • Company stock prices before and after public announcements related to oncology drugs.
    • Authors: Rothenstein JM, Tomlinson G, Tannock IF, Detsky AS
    • Issue date: 2011 Oct 19
    • [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    • Authors: Grevsen JV, Kirkegaard H, Kruse E, Kruse PR
    • Issue date: 2016
    • Just how good an investment is the biopharmaceutical sector?
    • Authors: Thakor RT, Anaya N, Zhang Y, Vilanilam C, Siah KW, Wong CH, Lo AW
    • Issue date: 2017 Dec
    DSpace software (copyright © 2002 - 2022)  DuraSpace
    Quick Guide | Policies | Contact Us | UMB Health Sciences & Human Services Library
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.